Business Context and Reporting Period
This Form 8-K reports on the results of the 2024 Annual Meeting of Stockholders held by Revolution Medicines, Inc. on June 20, 2024. The filing details the voting outcomes for three proposals presented to stockholders of record as of April 22, 2024.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a current report regarding corporate governance events rather than a financial statement.
Material Changes and Voting Results
Three proposals were voted upon at the Annual Meeting:
- Proposal 1 (Election of Directors): Stockholders elected three Class I directors.
- Elizabeth McKee Anderson: 107,146,109 votes For; 23,367,071 votes Withheld.
- Flavia Borellini, Ph.D.: 107,339,633 votes For; 23,173,547 votes Withheld.
- Lorence Kim, M.D.: 97,387,991 votes For; 33,125,189 votes Withheld.
- Proposal 2 (Ratification of Auditors): Stockholders ratified the appointment of PricewaterhouseCoopers LLP.
- Votes For: 148,105,275
- Votes Against: 9,895
- Abstentions: 67,350
- Proposal 3 (Say-on-Pay): Stockholders approved, on a non-binding advisory basis, the compensation of named executive officers.
- Votes For: 128,861,403
- Votes Against: 1,624,748
- Abstentions: 27,029
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is limited to the tabulation of stockholder votes.
Important Facts for Investors to Verify
- As of the record date, 170,493,095 shares of common stock were outstanding and entitled to vote, including 5,560,000 contingent earn-out shares.
- There were 17,669,340 broker non-votes recorded for the director election and say-on-pay proposals.
- All three proposals presented to the stockholders were approved.
- The newly elected directors will hold office until the 2027 annual meeting.